Mosaic Inverted Hemagglutinin Extracellular Vesicle Vaccines Elicit Protective Systemic and Mucosal Immunity against Heterosubtypic Influenza Infection.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41920585.
- Also identified by DOI 10.1021/acsnano.5c13363 and PMC identifier 13085848.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Developing innovative vaccine platforms and delivery strategies to induce broad, protective immunity in the respiratory tract is crucial for preventing influenza infection and transmission in potential epidemics and pandemics. In this study, we used cell-derived extracellular vesicles (EVs) as a vaccine platform to display mosaic human and avian influenza hemagglutinins (HAs) concurrently, including HA1/HA9/HA12 or HA3/HA4/HA10, on the EV surfaces. Immunization with the mosaic HA-EV vaccine elicited cross-reactive antibodies against influenza HA stalks and viruses, robust virus-specific cellular immune responses, and a balanced Th1/Th2 immune profile. Notably, the EVs demonstrated a promising application as an effective mucosal vaccine strategy, as evidenced by enhanced HA stalk- and virus-specific IgA in mucosal tissues and complete protection against heterosubtypic reassortant H7N9 and H5N1 virus infections in mice via intranasal immunization. EV-based mosaic HA vaccines hold great promise for developing universal influenza vaccines that target a mucosal route.
Medical subject headings
- Influenza Vaccines
- Extracellular Vesicles
- Immunity, Mucosal
- Hemagglutinin Glycoproteins, Influenza Virus
- Orthomyxoviridae Infections
- Influenza, Human